Investigation of Systemic Inflammation Markers in Lipedema
Systemic Inflammatory Indices in Lipedema Compared With BMI-Matched Obesity: The Distinct Clinical Relevance of the C-Reactive Protein-to-Albumin Ratio
The aim of this study is to evaluate systemic inflammation in individuals with lipedema using hematological and biochemical inflammation indices and to examine the relationship between these indices and clinical findings. Additionally, the study aims to evaluate whether systemic inflammatory markers serve as objective biomarkers reflecting lipedema progression and clinical severity, and to assess their practical applicability in clinical practice.
Hypothesis: Systemic inflammation markers are higher in the lipedema group compared to healthy controls, and these markers are associated with clinical severity.
연구 개요
상세 설명
Although the current literature demonstrates local inflammation secondary to microvascular dysregulation and macrophage infiltration at the subcutaneous adipose tissue level, the impact of this pathological cascade on systemic circulation has not been sufficiently investigated. This research aims to comprehensively elucidate the systemic inflammatory component of lipedema for the first time in the literature by analyzing the pro-inflammatory and immunoregulatory status in lipedema cases through objective, quantitative, and standardized hematological biomarkers such as systemic hematological and biochemical indices. Furthermore, it is believed that examining the correlation of this inflammatory load with clinical findings will contribute to understanding the progression mechanisms of lipedema.
The aim of this research is to determine whether indices derived from complete blood count and biochemical hematological data, which are routine and low-cost tests, are valid inflammatory biomarkers in the pathology of lipedema. The main expected benefit is to provide clinicians with new, non-invasive, rapid, and cost-effective parameters that can be used in the differential diagnosis, clinical staging, and determination of progression risk of lipedema. It is also thought that demonstrating the inflammatory basis of the disease at the systemic level will lay the groundwork for identifying future therapeutic targets (anti-inflammatory or immunomodulatory agents).
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Uskudar
-
Istanbul, Uskudar, 터키 (Türkiye)
- Department of Physical Medicine and Rehabilitation, Health Sciences University Sultan Abdulhamid Han Training and Research Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
1. Inclusion Criteria (Patient Group)
- Diagnosis of lipedema
- Female patients aged 18-65 years
- Literacy
- Signing the informed consent form to participate in the study
2. Inclusion Criteria (Obese-Overweight Control Group)
- Female patients aged 18-65 years
- Age and BMI matched with patients with lipedema
- Literacy
- Signing the informed consent form to participate in the study
3. Inclusion criteria (healthy control group)
- Being female, aged 18-65
- BMI <25
- Being literate
- Having signed the informed consent form by agreeing to participate in the study
Exclusion Criteria:
- Being under 18 or over 65 years of age
- Acute infection, autoimmune/rheumatological disease, malignancy, hematological disease, receiving steroid/immunosuppressive treatment
- Pregnancy
- Peripheral artery disease
- Severe cardiopulmonary failure (stage 3-4)
- Systemic diseases such as uncontrolled hypertension and diabetes
- Presence of cognitive impairment, hearing loss, communication difficulties that would hinder understanding of questionnaires and protocols
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Group 1: Female patients with lipedema
Female patients with lipedema
|
Demographic and clinical data will be recorded.
From the existing laboratory parameters in the system for all participants, the parameters suitable for the study, as described below, will be recorded.
Blood tests will not be requested from participants.
Only lipedema patients will be asked to complete the scales; in addition to clinical parameters, an ultrasound evaluation will be performed on lipedema patients.
No invasive procedures or treatments will be administered to the patients.
For all participants, the following laboratory parameters will be recorded: in the complete blood count, neutrophils, lymphocytes, monocytes, platelets, red blood cell distribution width , and mean platelet volume ; and in the biochemical analysis, C-reactive protein , erythrocyte sedimentation rate, and albumin levels.
Demographic and clinical data will be recorded.
From the existing laboratory parameters in the system for all participants, the parameters suitable for the study, as described below, will be recorded.
Blood tests will not be requested from participants.
For all participants, the following laboratory parameters will be recorded: in the complete CBC, neutrophils, lymphocytes, monocytes, platelets, red blood cell distribution width , and mean platelet volume ; and in the biochemical analysis, C-reactive protein, erythrocyte sedimentation rate, and albumin levels.
|
|
Group 2: Obese/overweight women
matched with female patients with lipedema based on age and BMI
|
Demographic and clinical data will be recorded.
From the existing laboratory parameters in the system for all participants, the parameters suitable for the study, as described below, will be recorded.
Blood tests will not be requested from participants.
For all participants, the following laboratory parameters will be recorded: in the complete CBC, neutrophils, lymphocytes, monocytes, platelets, red blood cell distribution width , and mean platelet volume ; and in the biochemical analysis, C-reactive protein, erythrocyte sedimentation rate, and albumin levels.
|
|
Group 3: Healthy women with a BMI<25
matched with female patients with lipedema of the same age
|
Demographic and clinical data will be recorded.
From the existing laboratory parameters in the system for all participants, the parameters suitable for the study, as described below, will be recorded.
Blood tests will not be requested from participants.
For all participants, the following laboratory parameters will be recorded: in the complete CBC, neutrophils, lymphocytes, monocytes, platelets, red blood cell distribution width , and mean platelet volume ; and in the biochemical analysis, C-reactive protein, erythrocyte sedimentation rate, and albumin levels.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Systemic Immuno-Inflammation Index (SII)
기간: Baseline
|
SII will be calculated as = Platelet × Neutrophil / Lymphocyte The SII index is calculated using hemogram parameters and indicates the balance between pro-inflammatory response and immunological regulation.
A high SII value indicates increased pro-inflammatory activity in the systemic circulation and/or suppressed lymphocytic immune response.
|
Baseline
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Neutrophil to Lymphocyte Ratio (NLR)
기간: Baseline
|
NLR: Calculated as Neutrophil/Lymphocyte .
A value of ~1-2 is considered physiological, 2-3 is a gray area or subclinical low-grade inflammation, and >3 is considered pathological or systemic inflammation.
It is used to predict disease severity and mortality risk in many diseases such as sepsis, pneumonia, cancer, and cardiovascular diseases.
There is no single, definitive cutoff value for all diseases; threshold values may vary depending on the situation.
|
Baseline
|
|
Platelet to Lymphocyte Ratio (PLR)
기간: Baseline
|
PLR: Calculated as Platelet/Lymphocyte.
It summarizes the combination of high platelets (pro-inflammatory/pro-thrombotic) and low lymphocytes (weakened immune response) in a single value.
|
Baseline
|
|
Monocyte to Lymphocyte Ratio (MLR)
기간: Baseline
|
MLR: Calculated as Monocyte/Lymphocyte. High MLR is associated with increased inflammation and impaired immune response.
|
Baseline
|
|
CRP to Albumin Ratio (CAR)
기간: Baseline
|
CAR: Calculated as CRP/Albumin.
It is an index reflecting both inflammation and nutritional/protein reserves.
|
Baseline
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Kruppa P, Gohlke S, Lapinski K, Garcia-Carrizo F, Soultoukis GA, Infanger M, Schulz TJ, Ghods M. Lipedema stage affects adipocyte hypertrophy, subcutaneous adipose tissue inflammation and interstitial fibrosis. Front Immunol. 2023 Jul 28;14:1223264. doi: 10.3389/fimmu.2023.1223264. eCollection 2023.
- Poojari A, Dev K, Rabiee A. Lipedema: Insights into Morphology, Pathophysiology, and Challenges. Biomedicines. 2022 Nov 30;10(12):3081. doi: 10.3390/biomedicines10123081.
- Duhon BH, Phan TT, Taylor SL, Crescenzi RL, Rutkowski JM. Current Mechanistic Understandings of Lymphedema and Lipedema: Tales of Fluid, Fat, and Fibrosis. Int J Mol Sci. 2022 Jun 14;23(12):6621. doi: 10.3390/ijms23126621.
- Amato AC. The Evolutionary Theory of Lipedema: A Perspective on Energy Storage and Chronic Inflammation. Cureus. 2025 Jul 26;17(7):e88809. doi: 10.7759/cureus.88809. eCollection 2025 Jul.
- Tel Adiguzel K, Yaman A, Kurklu NS, Adiguzel E. Dietary Inflammatory Index and Mediterranean Diet Score are associated with systemic inflammation in women with lipedema. Int J Obes (Lond). 2026 Feb;50(2):442-449. doi: 10.1038/s41366-025-01960-w. Epub 2025 Nov 27.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2026-93
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .